Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Type 1 Diabetes
NCT02641522Phase 1Completed
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in type 1 diabetes mellitus (T1D). Primary endpoint: Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
siltuximab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02641522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02641522.